NASDAQ:SVRA - Savara Stock Price, Forecast & News

Savara's stock was trading at $2.36 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, SVRA stock has decreased by 1.3% and is now trading at $2.33. View which stocks have been mosted impacted by Coronavirus.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Savara in the last year. There are currently 3 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Savara.

Savara is scheduled to release its next quarterly earnings announcement on Thursday, May 14th 2020. View our earnings forecast for Savara.

Savara Inc (NASDAQ:SVRA) posted its quarterly earnings data on Thursday, March, 12th. The company reported ($0.72) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.41) by $0.31. View Savara's earnings history.

6 equities research analysts have issued 1 year price objectives for Savara's shares. Their forecasts range from $1.00 to $17.00. On average, they anticipate Savara's share price to reach $8.60 in the next year. This suggests a possible upside of 269.1% from the stock's current price. View analysts' price targets for Savara.

News headlines about SVRA stock have been trending very positive on Monday, InfoTrie reports. The research group ranks the sentiment of news coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Savara earned a news sentiment score of 4.0 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the company's share price in the next few days. View the latest news aboutSavara.

Some companies that are related to Savara include ANI Pharmaceuticals (ANIP), Akero Therapeutics (AKRO), Sinovac Biotech (SVA), DiaMedica Therapeutics (DMCAF), Atreca (BCEL), AC Immune (ACIU), Kura Oncology (KURA), Morphic (MORF), RAPT Therapeutics (RAPT), G1 Therapeutics (GTHX), Catalyst Pharmaceuticals (CPRX), Provention Bio (PRVB), Neoleukin Therapeutics (NLTX), Avedro (AVDR) and Basilea Pharmaceutica (BPMUF).

Based on aggregate information from My MarketBeat watchlists, some companies that other Savara investors own include BIOLINERX LTD/S (BLRX), Agile Therapeutics (AGRX), Sorrento Therapeutics (SRNE), CEL-SCI (CVM), Gilead Sciences (GILD), Zynerba Pharmaceuticals (ZYNE), Verastem (VSTM), vTv Therapeutics (VTVT), Inovio Pharmaceuticals (INO) and Novavax (NVAX).

Savara trades on the NASDAQ under the ticker symbol "SVRA."

Savara's stock is owned by many different retail and institutional investors. Top institutional investors include Bain Capital Life Sciences Investors LLC (12.45%), Farallon Capital Management LLC (11.71%), EcoR1 Capital LLC (3.48%), Point72 Asset Management L.P. (2.16%), Geode Capital Management LLC (1.06%) and Jacobs Levy Equity Management Inc. (0.81%). Company insiders that own Savara stock include David A Ramsay, David L Lowrance, Jaakko Taneli Jouhikainen, Richard J Hawkins and Robert N Neville. View institutional ownership trends for Savara.

SVRA stock was sold by a variety of institutional investors in the last quarter, including Bank of New York Mellon Corp, and Bank of America Corp DE. Company insiders that have sold Savara company stock in the last year include David L Lowrance, Jaakko Taneli Jouhikainen, and Richard J Hawkins. View insider buying and selling activity for Savara.

SVRA stock was purchased by a variety of institutional investors in the last quarter, including Bain Capital Life Sciences Investors LLC, EcoR1 Capital LLC, Farallon Capital Management LLC, Point72 Asset Management L.P., Jacobs Levy Equity Management Inc., Renaissance Technologies LLC, Acadian Asset Management LLC, and Geode Capital Management LLC. Company insiders that have bought Savara stock in the last two years include David A Ramsay, and Robert N Neville. View insider buying and selling activity for Savara.

Shares of SVRA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of SVRA stock can currently be purchased for approximately $2.33.

Savara has a market capitalization of $118.46 million. The company earns $-78,170,000.00 in net income (profit) each year or $4.57 on an earnings per share basis.  View additional information about Savara.

The official website for Savara is http://www.savarapharma.com/.

Savara's mailing address is 6836 Bee Cave Road Building III Suite 200, Austin TX, 78746. The company can be reached via phone at 512-614-1848 or via email at [email protected]